Healthcare
Probi AB (publ)(PBBIF)
Live Price
Offline$24.00
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 β Mar 30, 2026
- Market Cap
- $286.93M
- Revenue Growth
- +4.9%
- EPS Growth
- -55.9%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 194 bars Β· Jun 23, 2025 β Mar 30, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Probi AB (publ) (PBBIF) is a Healthcare stock with a market cap of $286.93M and listed on OTC. The stock last traded around $24.00 and up 0.0% across the available one-year price window (Jun 23, 2025 β Mar 30, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of -55.9%, a dividend yield of 0.0%. What stands out right now is revenue +4.9%, EPS -55.9%, free cash flow -57.5% with operating margin 1.8% and ROIC 0.8%. Valuation already assumes a fairly strong business story at P/E 235.8 and price/sales 6.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PBBIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.9% vs +7.6% peer median
Operating Margin
Below sector median
+1.8% vs +19.4% peer median
P/E
Above sector median
235.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2024 was reported on Oct 22, 2024 with revenue below estimates by -11.5%.
The operating picture looks softer than before
Revenue is at +4.9% and EPS is at -55.9%, with operating margin around 1.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 Oct 22, 2024 | β | +0.0% | +0.0% | +0.0% |
2024 Jul 16, 2024 | β | +0.0% | +0.0% | +0.0% |
2024 Apr 23, 2024 | β | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PBBIF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
PBBIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PBBIF and SPY.
Company Overview
Probi AB (publ)
Other OTC
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Γrebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
- Leadership
- Anita Johansen
- IPO Date
- Oct 17, 2016
- Employees
- 157
- Street Address
- Ideongatan 1A
- Mailing
- Lund, 223 70
- Region
- Lund, SE
- Reporting Currency
- USD
- Investor Line
- 46 4 62 86 89 20
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 235.8
- EV/EBITDA
- 31.9
- Price/Sales
- 6.3
- Price/Book
- 2.9
Growth
- Revenue
- +4.9%
- EPS
- -55.9%
- Free Cash Flow
- -57.5%
Profitability
- Gross Margin
- 35.1%
- Operating Margin
- 1.8%
- Net Margin
- 2.7%
- ROE
- 1.2%
- ROIC
- 0.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 6.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.